Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Atreca, Inc. (BCEL : NSDQ)
 
 • Company Description   
Atreca is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. While more traditional oncology drug discovery approaches attempt to generate antibodies against known targets, Atreca?s approach relies on the human immune system to direct it to unique antibody-target pairs from patients experiencing a clinically meaningful, active immune response against their tumors. These unique antibody-target pairs represent a potentially novel and previously unexplored landscape of immuno-oncology targets.

Number of Employees: 134

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.84 Daily Weekly Monthly
20 Day Moving Average: 278,576 shares
Shares Outstanding: 37.76 (millions)
Market Capitalization: $69.48 (millions)
Beta: 0.78
52 Week High: $10.73
52 Week Low: $1.56
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -23.97% -16.75%
12 Week 4.55% 17.50%
Year To Date -39.27% -25.81%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
835 INDUSTRIAL ROAD SUITE 400
-
SAN CARLOS,CA 94070
USA
ph: 650-595-2595
fax: -
ir@atreca.com http://www.atreca.com
 
 • General Corporate Information   
Officers
John A. Orwin - President and Chief Executive Officer
Brian Atwood - Chairman of the Board of Directors
Herbert Cross - Chief Financial Officer
Kristine M. Ball - Director
Franklin Berger - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 04965G109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/10/22
Share - Related Items
Shares Outstanding: 37.76
Most Recent Split Date: (:1)
Beta: 0.78
Market Capitalization: $69.48 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.70 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.74 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/10/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.50
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 7.14%
vs. Previous Quarter: 17.72%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -65.05
12/31/21 - -58.28
09/30/21 - -49.11
ROA
03/31/22 - -49.58
12/31/21 - -47.38
09/30/21 - -41.33
Current Ratio
03/31/22 - 9.57
12/31/21 - 7.24
09/30/21 - 10.03
Quick Ratio
03/31/22 - 9.57
12/31/21 - 7.24
09/30/21 - 10.03
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 3.65
12/31/21 - 4.10
09/30/21 - 4.75
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©